RepliCel and YOFOTO receive all approvals to complete collaborative investment

by • September 25, 2018 • Feature Slider, Feature-Home, Featured-Slides-HomeComments Off on RepliCel and YOFOTO receive all approvals to complete collaborative investment256

Vancouver-based RepliCel Life Sciences Inc., a regenerative medicine company developing next-generation technologies in aesthetics and orthopedics, receives the conditional approval required to complete the investment that is part of a previously announced collaboration agreement with YOFOTO focused on commercialization of select RepliCel products in Greater China.

YOFOTO, (China) Health Industry Co. Ltd., has received all the approvals from the Chinese regulatory authorities required to finalize the transaction.

With the required approvals in place, the parties expect to close the investment portion of the Transaction shortly allowing them to then immediately and actively launch their strategic partnership in Greater China (Mainland China, Hong Kong, Macau, and Taiwan) and RepliCel’s next stage of activity outside of Asia.

The investment portion of the Transaction is a CDN $5,090,000 purchase of common shares at CDN $0.95 per share and will include 20 per cent warrant coverage exercisable at CDN $0.95 per share for a period of two years. The deal structure also includes milestone payments, sales royalties, and a commitment by YOFOTO to finance, over the next five years, the included RepliCel programs and an associated cell processing manufacturing facility in Greater China.

RepliCel believes aesthetic and orthopedic conditions affect approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often associated with aging, are caused by a deficit of healthy cells required for normal tissue healing and function.

Additionally, YOFOTO will collaborate with RepliCel on the further development and commercialization of RepliCel’s tendon regeneration cell therapy (RCT-01), skin rejuvenation cell therapy (RCS-01), and its injection technology for dermal applications (RCI-02) (excluding hair-related treatments) in Greater China.

“This investment represents a positive valuation of RepliCel by a commercially successful company having performed significant due diligence,” states RepliCel president and CEO, R. Lee Buckler. “We are very excited about what we have put in place while awaiting the completion of this transaction. Upon the closing of the investment, shareholders should expect to see RepliCel’s programs and activity gain significant momentum over the coming months with a particular focus on bringing its medical device to market. We will provide shareholders with more details on what this means in a comprehensive update as soon as the transaction has closed.”

Comments are closed.